Twist Bioscience (TWST) Receivables (2018 - 2026)

Twist Bioscience has disclosed Receivables across 9 years of filings, most recently posting $72.5 million for Q1 2026.

• In Q1 2026, Receivables rose 41.08% year-over-year to $72.5 million; the TTM figure through Mar 2026 stood at $72.5 million (up 41.08% YoY), while the FY2025 annual figure was $60.9 million, up 64.82% from the prior year.
• Receivables climbed to $72.5 million in Q1 2026, from $62.4 million in the prior quarter.
• Over the last five years, Receivables for TWST reached as high as $72.5 million in Q1 2026 and fell as low as $34.6 million in Q2 2024.
• The 5-year median for Receivables is $46.9 million (2023), against an average of $47.9 million.
• Annual changes were most pronounced in 2022 — Receivables soared 2084.7% — and 2024, when it declined 28.16%.
• A 5-year view of Receivables shows it stood at $49.7 million in 2022, then retreated by 23.82% to $37.9 million in 2023, then grew by 8.71% to $41.2 million in 2024, then soared by 51.54% to $62.4 million in 2025, then grew by 16.33% to $72.5 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $72.5 million, $62.4 million, and $60.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.